DNA X amends 8-K to update disclosure on Series B preferred stock sale for $2.5 million

• DNA X filed an amended 8-K to update its disclosure under Item 3.02 on unregistered equity sales.
• It reported selling the remaining 416,667 shares of Series B Preferred Stock on Aug. 7 for cash proceeds of $2.5 million.
• Pro forma stockholders’ equity was estimated at $5.84 million as of Aug. 7, above Nasdaq’s $2.5 million continued-listing requirement.
• The company is awaiting Nasdaq’s formal determination that it has regained compliance with the stockholders’ equity rule.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DNA X Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-037733), on August 13, 2026, and is solely responsible for the information contained therein.